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Summary
Aim: To examine the effect of glyceryl trinitrate (GTN), a nitric oxide (NO) donor compound, on the concurrent progression of cartilage and
subchondral bone changes in an ovine meniscectomy model of osteoarthritis (OA).
Methods: Bilateral lateral meniscectomy (MX) was performed on 12 ewes to induce OA. Six were treated with topical GTN (0.7 mg/kg twice
weekly) (MXCGTN). Six other sheep formed non-operated controls (NOC). After sacriﬁce at six months, the subchondral bone density (BMD)
of the lateral and medial femoral condyles (LFC, MFC) and tibial plateau (LTP, MTP) was assessed by DEXA. Dynamic biomechanical testing
was performed across the MTP and LTP. Histological sections from each region were scored qualitatively and the thickness of the
subchondral bone plate (SCB) was determined by image analysis.
Results: MXCGTN displayed signiﬁcantly greater SCB thickness relative to MX in the LFC (mean increaseC88% andC42%, respectively)
and the MFC. SCB BMD was 10e12% greater in MXCGTN relative to MX in the LFC, LTP and MTP. MXCGTN sheep also showed greater
increases in some histopathology variables, greater central erosion of the LTP, and changes in dynamic stiffness (decreased) and phase lag
(increased) in the outer zone of the LTP.
Conclusions: Treatment with GTN signiﬁcantly increased subchondral bone thickness and density during subchondral remodelling following
meniscectomy. In addition, it slightly but signiﬁcantly worsened degeneration of cartilage structure and function. These results suggest that
clinical use of GTN may accelerate both cartilage degeneration and subchondral bone sclerosis if used in the presence of OA, and
demonstrate that NO has the potential be an important mediator of the subchondral bone changes seen in OA.
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Nitric oxide (NO) is a highly reactive, gaseous free radical
that has been implicated in the pathogenesis of osteoar-
thritis (OA). Synovial ﬂuid levels of nitric oxide are elevated
in arthritic joints1, and osteoarthritic chondrocytes show
elevated expression of the generative enzyme inducible
nitric oxide synthase (iNOS)2. Nitric oxide is thought to
induce a range of disturbances in chondrocyte metabolism,
including suppression of proteoglycan (PG) synthesis3,
increased matrix degradation4, and chondrocyte apopto-
sis5. Animal studies using iNOS knockout models and iNOS
inhibiting agents have demonstrated a clear role for NO in
the progression of arthritis6,7.
In addition to a direct inﬂuence on chondrocytes, it is also
possible that NO may inﬂuence the progression of
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Received 28 March 2004; revision accepted 26 August 2004.97osteoarthritic cartilage damage through altered metabolism
of the underlying subchondral bone (SCB). In bone,
constitutive local production of NO appears to support the
growth and activity of both osteoblasts and osteoclasts8.
However, higher levels of NO, such as those induced by
cytokine stimulation, inhibit osteoclast function and differ-
entiation of osteoclasts from precursor cell types, as well as
inhibiting osteoblast maturation and activity8e10. Induced
production of NO may represent a protective mechanism
against cytokine-stimulated bone resorption in pathological
conditions11.
While the in vitro effects of NO in bone are somewhat
variable11, its dominant role in vivo appears to be tonic
inhibitory restraint of bone resorption. This is supported by
the observation that in rats, the iNOS inhibitor amino-
guanidine potentiates loss of bone mineral density12.
Wimalawansa et al. have demonstrated that topical use of
an NO donor (glyceryl trinitrate) alleviates both ovariecto-
my-induced and prednisolone-induced bone loss in
rats13,14. A pilot trial in humans has also shown that glyceryl
trinitrate effectively counteracts bone loss after ovariectomy
in women15.
Glyceryl trinitrate (GTN) is a lipophilic organic nitrate
rapidly cleaved in vivo to inorganic nitrite, then nitric oxide.4
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years as a vasodilator and symptomatic treatment for
angina pectoris, hypertension, and congestive heart failure.
On the basis of the above studies, together with the
observation that nitrate use is associated epidemiologically
with increased hip and heel bone mineral density (BMD)16,
it has been proposed that GTN may represent an effective
treatment for osteoporosis and other forms of osteopenia17.
However, given the known deleterious effects of NO on
chondrocytes, and the protective effect of iNOS inhibitors in
experimental arthritis7, it is reasonable to question the
safety of nitrates in joint tissues. Our previous studies have
shown that intermittent, topical administration of GTN to
normal sheep induced signiﬁcant structural and biome-
chanical alterations within femoro-tibial articular cartilage18.
This is supported by recent epidemiological evidence of an
association between nitrate use and hip OA in elderly
women19. Furthermore, high BMD is itself a risk factor for
OA20. Given also that subchondral bone sclerosis is
a histological hallmark of OA, and is suspected by some
authors to be central to its pathogenesis21, it is possible that
nitrate use may increase OA risk by increasing subchondral
bone mass19. The aim of this study was to examine the
effect of GTN treatment on the concurrent progression of
articular cartilage and subchondral bone changes in the
well-characterised ovine meniscectomy model of OA22,23.
Method
ANIMAL TREATMENTS
Eighteen aged (7 years old) Merino ewes, selected for
uniformity of size and conformation, were purchased from
a single source. Twelve sheep were subjected to bilateral
lateral meniscectomy to induce osteoarthritis, as described
previously22,23. Operated animals received cefazolin sodi-
um, ﬂunixin meglumine, and slow-release fentanyl patches
in the peri-operative period. After a brief recovery period, all
sheep were housed on irrigated pasture for the remainder of
the trial period. Beginning 2 weeks after surgery, six of the
meniscectomised animals were treated with 2% GTN oint-
ment [Nitro-Bid, Hoescht, Australia], applied twice weekly
(0.7 mg GTN/kg body weight) to the hairless region on the
medial aspect of the hindlimb. This dosage regime was
selected to provide a similar weight-adjusted weekly dosage
(though at lower frequency) to that used in the rat studies of
Wimalawansa et al.13,14. The treatment groups (nZ 6) were
therefore: non-operated control (NOC), meniscectomised
(MX), and GTN-treated meniscectomised (MXCGTN). All
animal procedures were approved by the Murdoch Univer-
sity Animal Ethics Committee (AEC R779/00).
HISTOPATHOLOGICAL ASSESSMENT
Animals were euthanased after 6 months (24e26 weeks)
of treatment, by intravenous injection of pentobarbitone.
One hindleg (random left or right) was used for DEXA,
biomechanical testing and tibial plateau histology, while the
other was used for assessment of gross pathology
(cartilage erosions and osteophyte development) and
femoral condyle histology, as described previously18.
Decalciﬁed histological sections were prepared from mid-
condyle, medio-lateral osteochondral slices of the medial
and lateral tibial plateau (MTP, LTP) and medial and lateral
femoral condyles (MFC, LFC), and stained with toluidine
blue and Masson’s trichrome23. Semi-quantitative histopa-
thological grading was performed according to a publishedmodiﬁed Mankin’s scoring system24. In each joint region,
four zones were scored: inner, middle, outer, and outer
marginal zones. Scoring was done by a single observer,
according to a six-point scale (structure, cellularity, chon-
drocyte cloning, territorial toluidine blue staining, interterri-
torial toluidine blue staining, calciﬁed cartilage structure),
and a mean aggregate score determined as the average of
these four zones. In addition, calciﬁed cartilage vascularity
was measured as the number of blood vessels invading the
length of the calciﬁed cartilage layer, excluding regions of
osteophytic remodeling25.
Subchondral bone plate thickness was measured using
computer-assisted image analysis as described pre-
viously18. Image analysis software [ImagePro Plus v3.0.1;
Media Cybernetics, USA] containing an algorithm for radial
thickness measurement was used to determine the mean
distance (mm) between lines delimiting the most advanced
tidemark and limit of subchondral bone (intertrabecular
spaces !500 mm), after dividing the cartilage visually into
three equal arc segments termed the outer, middle, and
inner zones. In addition, the cross-sectional area (mm2) of
osteophytic remodeling was determined by image analysis.
DYNAMIC BIOMECHANICAL TESTING
The biomechanical properties of tibial plateau articular
cartilage were assessed using a hand-held indentation
device26, as described previously27. Brieﬂy, testing was
completed at each of 18 locations according to a 3! 3
array marked on each condyle. At each location, the
indentation probe was pressed against the surface with
constant pressure whilst a ﬂat cylindrical non-porous
indenter (0.7 mm diameter) applied a sinusoidal oscillation
(20 Hz) to the cartilage surface. Dynamic stiffness and
phase lag were determined directly whilst dynamic shear
modulus (G*), was calculated by adjusting for thickness
using the theory of Hayes et al.28. On completion of
biomechanical testing, articular cartilage thickness was
determined at each location by needle penetration29.
Results of biomechanical testing at individual locations
are pooled for reporting (but not statistical analysis) into
subsets corresponding to the equivalent outer (O), middle
(M), and inner (I) zones of the lateral (L) or medial (M)
plateau (nZ 6 zones: MO, MM, MI; LO, LM, LI), as
described previously18.
BONE DENSITOMETRY
Subchondral bone mineral density was determined in the
LTP, MTP, LFC, and MFC using a Hologic QDR 4500-W
absorptiometer [Hologic Inc., USA]30. A bed of rice of
constant thickness (5 cm) was used both to position the
specimen and to simulate soft-tissue density. Scanning of
subchondral sites was conducted such that the weight-
bearing articular surface was parallel to the beam. Bone
density (gm/cm2) was determined as the mean of three
5! 3 mm regions-of-interest (ROI), in the inner, middle and
outer subchondral zones of the tibial plateau, and three
3! 3 mm ROI in the corresponding zones of the femoral
condyles.
ASSAY OF BONE MARKERS
Osteocalcin was assayed in serum collected prior
to euthanasia, by a commercial pathology laboratory
utilising competitive radioimmunoassay. Brieﬂy, 125I-bovine
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and normal rabbit serum were combined with the test
sample or bovine osteocalcin standard and incubated for
48 h at 4(C. Antibody complexes were precipitated by
addition of an anti-rabbit gamma globulin precipitating sera
and counted by routine gamma counting. Antisera raised
against bovine osteocalcin have been shown to cross-react
with both human and ovine osteocalcin31.
Pyridinoline and deoxypyridinoline were assayed in urine
collected at necropsy, using a published high performance
liquid chromatography (HPLC) method32. Assayed levels
were corrected for urine creatinine concentration, as
determined by modiﬁed Jaffe reaction33.
STATISTICAL ANALYSIS
All data presented express meanG standard deviation,
except for graphical ﬁgures which present meanG stan-
dard error. Statistical comparisons were generated using
specialist software [Statview 5.0, SAS Institute Inc., USA],
using analysis of variance (ANOVA) to analyse variance
across groups, and Fisher’s protected least signiﬁcant
difference (Fisher’s PLSD) test to compare means between
groups. When multiple zones or testing locations were
compared simultaneously to examine differences across an
entire region, zone (inner, middle, or outer) or location was
included as a second independent variable. A signiﬁcance
level of PZ 0.05 was used throughout.
Results
BODY WEIGHT
Meniscectomised sheep lost an average of 5.6 kg body
weight during the month following surgery. GTN treatment
had no inﬂuence on body weight at any time point. No side
effects or behavioural differences were observed in GTN-
treated animals.
CARTILAGE DATA
As previously described, meniscectomy was associated
with gross cartilage erosion and prominent osteophyte
development24. Gross changes were mostly limited to the
meniscectomised lateral compartment. GTN treatment had
no effect on subjective scores for cartilage erosion or
osteophyte development (Table I).
Aggregate histopathology scores (Table I) were in-
creased in all regions in meniscectomised animals, espe-
cially the lateral compartment. Aggregate scores did not
differ between treated and non-treated meniscectomised
sheep. However, MXCGTN animals were found to have
signiﬁcantly greater scores relative to MX sheep for
structural damage (1.96 vs 1.17, PZ 0.033; NOC 0.65)
and loss of interterritorial staining (1.17 vs 0.58, PZ 0.003;
NOC 0.25) in the MFC, and greater scores for chondrocyte
cloning in the LFC (3.37 vs 2.67, PZ 0.015; NOC 0.33).
After meniscectomy, scores for both calciﬁed cartilage
pathology and vessel number (Table I) were increased in all
regions (P! 0.0001 for both variables), especially the
lateral compartment. MXCGTN sheep had a greater
number of vessels invading calciﬁed cartilage in the LFC,
relative to MX animals (PZ 0.031). However, scores for
both calciﬁed cartilage pathology (1.25 vs 1.96, PZ 0.023;
NOC 1.21) and vessel number (Table I, PZ 0.010) were
lower than MX sheep in the MTP.After meniscectomy, cartilage thickness decreased in the
inner regions of both tibial condyles and increased in the
outer regions (Fig. 1). MXCGTN had signiﬁcantly thinner
cartilage in the eroded middle regions of the LTP relative to
MX (PZ 0.0034). Dynamic shear modulus (G*) was
signiﬁcantly lower in all meniscectomised groups
(P! 0.0001), primarily due to changes in the LTP. G*
was signiﬁcantly lower in MXCGTN sheep relative to MX
in the outer locations of the LTP (PZ 0.039). G* data
obtained in the middle locations of the LTP were found to
have a high degree of error due to deep cartilage erosion in
some animals exposing much stiffer subchondral tissues.
Phase lag values of MXCGTN sheep were increased
overall relative to MX (12.38G 3.26 vs 11.46G 2.38;
PZ 0.018), but were not signiﬁcantly different from those
of NOC sheep (12.08G 2.30). However, phase lag values
of MXCGTN sheep did differ from NOC in some zones,
notably a signiﬁcant increase in the outer LTP (PZ 0.032)
and a signiﬁcant decrease in the outer MTP (PZ 0.017).
The latter change was also observed in MX animals.
SUBCHONDRAL BONE DATA
After meniscectomy, the SCB (Fig. 2) of MX animals was
signiﬁcantly thicker in the outer zone of the LFC (PZ 0.035)
and LTP (PZ 0.008), while thinning of the SCB was
observed in the outer zone of the MFC (PZ 0.034).
MXCGTN animals showed signiﬁcantly greater increase
in SCP thickness relative to MX in the middle zone of the
LFC (PZ 0.024), and reduced loss of bone thickness in the
outer zone of the MFC (PZ 0.049).
Osteophyte size (Table I) was greatest in the femoral
condyles. MXCGTN sheep showed greater osteophyte
growth relative to MX ewes in the MFC (PZ 0.026), with
a similar trend in the LFC (PZ 0.062).
After meniscectomy, subchondral BMD (Fig. 3) was
increased in the LFC (PZ 0.002) and LTP (PZ 0.018),
and decreased in the MFC (PZ 0.0003) and MTP
Table I
Effect of meniscectomy (MX) and glyceryl trinitrate (GTN) on
histopathological variables in the lateral and medial femoral
condyles (LFC, MFC) and tibial plateau (LTP, MTP).
NOC MX MXCGTN
Cartilage gross
score (max.Z 16)
2.67G 2.42 11.33G 1.97*** 11.50G 2.68***
Osteophyte gross
score (max.Z 12)
0.17G 0.41 9.00G 2.28*** 10.5G 2.43***
Mean aggregate histopathology score (max.Z 30)
LFC 3.21G 0.29 14.83G 2.18*** 15.12G 4.02***
MFC 2.55G 0.60 6.96G 1.86*** 8.00G 1.70***
LTP 3.31G 0.43 16.75G 1.67*** 16.21G 2.76***
MTP 2.33G 1.72 8.87G 2.47** 9.46G 3.97***
Number of blood vessels penetrating calcified cartilage zone
LFC 0.83G 0.41 4.00G 1.79 8.167G 6.56**y
MFC 1.17G 1.60 2.83G 1.33 2.33G 2.42
LTP 1.33G 1.21 4.50G 2.07* 5.67G 1.75**
MTP 2.17G 1.60 5.17G 2.93* 2.00G 1.67y
Osteophyte cross-sectional area (mm2)
LFC e 25.12G 10.71 40.40G 14.28a
MFC e 2.00G 1.90 6.97G 5.11y
LTP e 12.13G 3.86 13.28G 6.56
MTP e 2.25G 1.62 1.91G 2.02
The symbol * differs from NOC (*P! 0.05, **P! 0.005,
***P! 0.0005); yMXCGTN differs from MX (P! 0.05);
a(PZ 0.06 vs MX)
977Osteoarthritis and Cartilage Vol. 12, No. 12(P! 0.0001). MXCGTN sheep showed a greater increase
in subchondral BMD in the LFC (PZ 0.019) and LTP
(PZ 0.011), and reduced loss of BMD in the MTP
(PZ 0.023), relative to MX. When compared by zone,
these differences were most prominent in the middle zone
of the LFC, and the outer zones of the LTP and MTP.
BONE MARKERS
At the time of sacriﬁce, serum osteocalcin levels (Fig. 4)
were signiﬁcantly increased in MX sheep relative to NOC
animals (PZ 0.020). Levels in MXCGTN animals were
signiﬁcantly lower relative to MX (PZ 0.004), and did not
differ from those of NOC sheep. Urinary levels of pyridino-
line and deoxypyridinoline (Fig. 4) did not differ signiﬁcantly
between treatment groups, though MXCGTN sheep
showed a tendency towards lower levels of pyridinoline
0
2
4
6
8
10
12
14
0
0.2
0.4
0.6
0.8
1
1.2 NOC
MX
MX+GTN
OUTER MIDDLE INNER ALL MIDDLE OUTERINNERALL
LATERAL TIBIA MEDIAL TIBIA
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
*
*
†
* *
* *
*
*
†
*
†
* *
†
*
*
†
* *
*
*
†
*
*
*
Shear
modulus
Phase lag
Thickness
Th
ic
kn
es
s 
(m
m)
Ph
as
e 
(de
gre
es
)
G
*
 
(M
Pa
)
Fig. 1. The effect of meniscectomy (MX) and glyceryl trinitrate
(GTN) on articular cartilage shear modulus (G*, MPaG SE), phase
lag (degreesG SE) and cartilage thickness (mmG SE) at testing
locations in outer, middle, and inner zones of the tibial plateaux.
Central columns represent the mean of all test locations in the
lateral (left) and medial (right) tibial plateau. The symbol * differs
signiﬁcantly from NOC (P! 0.05); yMXCGTN differs from MX
(P! 0.05).and deoxypyridinoline compared to MX animals, which
mirrored the changes seen in serum osteocalcin.
Discussion
In this trial, treatment with GTN was found to signiﬁcantly
affect the structural alterations seen in cartilage and bone
following meniscectomy. While there was no grossly visible
difference in cartilage pathology or osteochondral remodel-
ling, other measures suggest that the cartilage of GTN-
treated animals was degraded to a greater degree
compared to untreated animals. MXCGTN animals
showed thinner cartilage at central testing points in the
LTP, suggesting greater severity of articular cartilage
erosion. Though aggregate scores were not signiﬁcantly
different in MXCGTN sheep, histopathological scoring
revealed greater structural degeneration and loss of PG in
the MFC, and a greater degree of chondrocyte cloning in
the LFC relative to MX animals.
The cartilage of GTN-treated animals was also bio-
mechanically inferior, with an overall increase in phase lag,
and a greater reduction in dynamic shear modulus (G*) in
the outer zones of the LTP, relative to MX sheep. These
locations (LO) correspond to areas previously protected by
the meniscus prior to surgery, and were found to have the
greatest alterations following meniscectomy in both this
study and in the topographical analyses of Appleyard
et al.27. The dramatic loss of cartilage dynamic stiffness in
OA is thought to be due to ﬁbrillation and rupture of collagen
of the collagen meshwork, and loss of PG-supplied collagen
pre-stress34,35. Increased cartilage phase lag has also been
reported in experimental models of OA, and is thought to
reﬂect increased frictional energy dissipation due to
loosening of collagenePG interactions, as well as pro-
teolytic degradation of PGs27,36. Though phase lag was not
altered overall in MXCGTN sheep relative to NOC,
a signiﬁcant increase was observed in the outer zones of
the LTP. Together, both the structural and biomechanical
results suggest that topical treatment with GTN worsened
cartilage degeneration following lateral meniscectomy.
However, the lack of a consistent increase in phase lag in
the untreated MX group was unexpected, and may cast
doubt on the signiﬁcance of this particular variable.
As has been shown previously in this model23,37,
signiﬁcant remodelling of subchondral bone was evident 6
months after the induction of osteoarthritis by meniscec-
tomy. The subchondral bone plate was thickened in the LFC
but thinner in the outer MFC of meniscectomised animals,
reﬂecting the altered pattern of loading in the meniscus-
deﬁcient joint, whereby external femoral rotation and slight
varus displacement of the stiﬂe increases loading in the
lateral compartment. Changes in the tibial plateau were
concentrated in the outer zone of the LTP, the region
normally protected by the meniscus in the intact joint.
Changes in peri-articular bone mineral density showed
a similar pattern, with increased BMD in the lateral
compartment and relative osteopenia in the medial side of
the joint. The observation that BMD changes were more
prominent than altered SCP thickness is interesting, as the
classic concept of subchondral bone changes in OA
involves a sclerotic but hypomineralised matrix38. Karvonen
et al. used a similar DEXA method to show a signiﬁcant
decrease in peri-articular BMD in patients with early knee
OA39. Early loss of subchondral bone volume and density is
also common in unilateral surgical animal models of OA, due
to decreased loading of the joint40,41. The use of a bilateral
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Fig. 2. Subchondral bone plate thickness (mmG SE) by zone in the lateral and medial femoral condyles (LFC, MFC) and tibial plateau
(LTP, MTP) of NOC (,), MX ( ), and MXCGTN sheep (-). The symbol * differs signiﬁcantly from NOC (P! 0.05); yMXCGTN differs from
MX (P! 0.05).meniscectomy model in this study prevented unloading
through shift of weight to the contralateral limb, though
compensatory gait changes may still have reduced peak
loads on the stiﬂe joints. Joint loading was also affected by
the slight (w11%) loss of body weight recorded following
meniscectomy; this is likely to be the result of post-surgical
stress and/or an effect of subclinical lameness on grazing
behaviour23. Results in this surgical OA model show that it is
possible (as in the LTP in this study) for a signiﬁcant
increase in subchondral BMD to occur, accompanied by
only minor thickening of the subchondral plate. However, the
concurrent loss of bone in the medial compartment of thesame joint suggests that primarily mechanical, rather than
biochemical changes were responsible for these subchon-
dral bone changes; this model may therefore not directly
reﬂect the subchondral changes of naturally-occurring OA.
Glyceryl trinitrate treatment signiﬁcantly inﬂuenced the
subchondral bone remodelling processes associated with
meniscectomy. GTN-treated animals showed a greater
increase in subchondral bone plate thickness in the middle
(in-contact) zone of the LFC, and reduced loss of thickness
in the outer zone of the MFC, relative to MX sheep (Fig. 2).
Similarly, treated animals showed a greater increase in
subchondral bone density in the LFC and LTP, and lessFig. 3. Boxplots of subchondral bone mineral density (BMD, gm/cm2) in the lateral and medial femoral condyles (LFC, MFC) and tibial plateau
(LTP, MTP) of NOC (,), MX ( ), and MXCGTN sheep ( ). Box indicates 25the75th percentile, line indicates 10the90th percentile, line
indicates median, dot indicates mean. The symbol * differs signiﬁcantly from NOC (P! 0.05); yMXCGTN differs from MX (P! 0.05).
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yMXCGTN differs from MX (PZ 0.0023).loss of BMD in the MTP (Fig. 3). Induction of endogenous
NO production in bone is thought to be a protective
response against cytokine-stimulated bone resorption in
pathological conditions9,11. NO is known to inhibit both
osteoclast function and osteoclast differentiation from pre-
cursor cell types10. GTN, as an exogenous donor of nitric
oxide, appears to have had a similar bone-promoting effect
in this study. It has been proposed by Fazzalari et al. that
a different set of mediators might predominate in the
remodelling processes of OA subchondral bone, compared
to those operative during normal homeostatic turnover,
such as the osteoprotegerin/receptor activator of nuclear
factor kappa-b ligand (OPG/RANKL) axis42. Hilal et al.
reported an alteration of subchondral bone metabolism in
OA patients, suggesting that local release of inﬂammatory
mediators may be at least as important in subchondral bone
remodelling as mechanical stimuli43. The pronounced
inﬂuence of exogenous NO in this study suggests that
endogenously generated nitric oxide has the potential to be
a prime mediator of the subchondral bone plate sclerosis
that typically occurs in OA joints. However, the observed
responses may again relate to mechanical factors peculiar
to this surgical model; NO has been shown to potentiate
mechanically induced bone formation in rat vertebrae44.
GTN treatment also appeared to promote osteophytic
remodelling, increasing the cross-sectional area of marginal
osteophytes especially in the femoral condyles. Reports of
reduced osteophyte growth in arthritic iNOS-deﬁcient
mice45 and in osteoarthritic dogs treated with a selective
iNOS inhibitor46 support this association.
Tidemark alterations and neovascularisation of the
calciﬁed cartilage layer were prominent following meniscec-
tomy in this trial. Possibly due to the advanced age of the
subjects, multiple tidemarks were present in nearly all
sheep, including control animals. However, blood vessels
were seen to invade the calciﬁed cartilage in greater num-
ber and to a greater depth in meniscectomised animals,
particularly in the lateral joint compartment. GTN treatment
signiﬁcantly altered the pattern of calciﬁed cartilage neo-
vascularisation following meniscectomy. An increased
NO is known to promote angiogenesis in other tissues,
possibly by feedback interaction with ﬁbroblast growth
factor-2 (FGF-2)47. The GTN-induced increase and
decrease in vessel number observed in the LFC andMTP, respectively (Table I), mirrored local subchondral
bone responses, suggesting that the effect of NO was
dependent on other metabolic or mechanical lesions extant
in this model.
Serum osteocalcin levels (a marker of bone formation)
were signiﬁcantly increased in meniscectomised sheep.
This suggests an increase in bone formation (or bone
turnover) in these animals, and was seen despite a slight
loss of body weight. Stress is unlikely to have caused this
elevation, as it has been shown in sheep that while short-
term stresses such as handling or transport do not inﬂuence
osteocalcin levels, long-term corticosteroid administration
reduces plasma levels31. Human studies have shown both
elevated43,48 and reduced49,50 osteocalcin levels in OA
patients. Serum osteocalcin levels of GTN-treated sheep
were signiﬁcantly lower than those of MX animals, and
similar to NOC sheep. Urinary collagen cross-links (markers
of bone resorption) showed a similar (but not statistically
signiﬁcant) trend, with GTN reversing a meniscectomy-
associated increase in pyridinoline and deoxypyridinoline
excretion. This suggests that GTN treatment attenuated an
increase in bone turnover following meniscectomy. This
ﬁnding was in contrast to both human and rat trials, in which
topical GTN treatment did not affect the ovariectomy-
induced increase in serum osteocalcin or deoxypyridinoline
levels15,51,52.
Previous topographical studies of the cartilage and bone
changes in this OA model23,27,30 have shown that the ob-
served structural alterations reﬂect altered joint kinematics
consequent to loss of the important stabilizing and load-
distributing roles of the meniscus. Bone changes particu-
larly mirror altered loading patterns, with a relative increase
in bone formation in the middle and outer zones of the LFC
and LTP, and relative bone loss in the outer MFC and
MTP23,30. In this study, GTN treatment signiﬁcantly inﬂu-
enced post-meniscectomy changes in SCB thickness and/
or density in four of these six regions (middle LFC, outer
LTP, outer MFC, outer MTP). However, in less affected
regions (e.g., middle MFC) GTN treatment had no apparent
inﬂuence. Thus, GTN appears to have accentuated post-
meniscectomy bone formation whilst simultaneously reduc-
ing post-meniscectomy bone loss, without a global effect
on SCB thickness or density. Cartilage lesions induced by
meniscectomy show a slightly different distribution, with net
980 M. A. Cake et al.: NO donor accelerates OA bone sclerosisthickening of cartilage predominant except at sites of focal
erosive lesions23,27,30. Appleyard et al.27 found that post-
meniscectomy alterations in cartilage composition and
biomechanical integrity were most marked in the outer
and middle zones of the LTP, sites previously protected by
the meniscus. Thus, the effect of GTN on G* and phase lag
in the outer LTP, and increased loss of cartilage in the
middle LTP, are highly signiﬁcant within the context of the
lesions induced by this model and are again consistent with
a local worsening of key pathology rather than a clear global
inﬂuence on joint tissue structure.
In summary, intermittent topical treatment with GTN, an
efﬁcient NO donor compound, was found to subtly but
signiﬁcantly worsen cartilage degeneration following ovine
meniscectomy. This is consistent with the known adverse
effects of NO in cartilage in other models, and complements
ﬁndings of altered cartilage structure and function in GTN-
treated normal sheep in a similar previous study18.
Secondly, GTN treatment signiﬁcantly increased subchon-
dral bone thickness and density during subchondral
remodelling following lateral meniscectomy, whilst periph-
eral markers suggested a reduction in bone turnover. It has
been proposed that the local bone sclerosis accompanying
OA results in a stiffer, less compliant subchondral plate,
thereby increasing compressive forces on the overlying
chondrocytes and accelerating cartilage degeneration21.
The results of this study provide evidence that clinical use of
NO donor compounds such as GTN may accentuate bone
sclerosis and contribute to disease progression if used in
the presence of OA. Furthermore, the changes observed
here suggest that nitric oxide has the potential be an
important mediator of the subchondral bone changes seen
in OA.
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